TerminatedNCT04125290
US Post-Marketing Safety Study of Moxetumomab Pasudotox-tdfk (LUMOXITI)
Studying Classic hairy cell leukemia
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- AstraZeneca
- Principal Investigator
- Archna HaleAstraZeneca
- Enrollment
- 2 enrolled
- Eligibility
- All sexes
- Timeline
- 2019 – 2021
Study locations (2)
- Rocky Mountain Cancer Centers, Pueblo, Colorado, United States
- Research Site, Bridgeton, Missouri, United States
Collaborators
Iqvia Pty Ltd
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT04125290 on ClinicalTrials.govOther trials for Classic hairy cell leukemia
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE1, PHASE2NCT06965114Testing the Combination of Anti-cancer Drugs, Tovorafenib Plus Rituximab, in Patients With Hairy Cell LeukemiaNational Cancer Institute (NCI)
- RECRUITINGNANCT06781515Assessment of Disease Burden in Hairy Cell LeukemiaIRCCS Azienda Ospedaliero-Universitaria di Bologna
- RECRUITINGPHASE2NCT06311227Venetoclax for the Treatment of Patients With Relapsed Hairy Cell LeukemiaNational Cancer Institute (NCI)
- RECRUITINGNCT06774677Decoding the Extracellular Vesicles-driven Communication in the Microenvironment of Hairy Cell Leukemia to Improve Patient Care ManagementIRCCS Azienda Ospedaliero-Universitaria di Bologna
- RECRUITINGNCT06764524Hairy Cell Leukemia: Harnessing the Full Power of Extracellular Vesicles to Improve Patient Care ManagementIRCCS Azienda Ospedaliero-Universitaria di Bologna
- RECRUITINGPHASE2NCT06561360A Study of Vemurafenib and Obinutuzumab Compared to Cladribine and Rituximab in People With Hairy Cell Leukemia (HCL)Memorial Sloan Kettering Cancer Center
- RECRUITINGPHASE1NCT06340737AutologousCD22 Chimeric Antigen Receptor (CAR)T Cells in w/Recurrent/Refractory B Cell LymphomasStanford University
- RECRUITINGPHASE1NCT04815356Phase I Study of Anti-CD22 Chimeric Receptor T Cells in Patients With Relapsed/Refractory Hairy Cell Leukemia and VariantNational Cancer Institute (NCI)